CT-ISG
Europe’s IT and business services market grew only slightly in the second quarter, as slowing demand for managed services largely offset a sharp rise in spending on cloud-based services, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.
The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows ACV for the combined market (both managed services and cloud-based as-a-service) rose 1 percent, to US $7.7 billion, in the second quarter. Since bottoming out in the third quarter of last year, the combined market has grown sequentially for three straight quarters to reach its second-highest quarterly ACV ever in Q2.
“Having rebounded from the trough of last year’s downturn, the European market is now on a slow growth trajectory, with sluggish demand for managed services impeding overall growth,” said Steve Hall, president, ISG EMEA. “Cost optimization remains the primary driver of managed services demand, while decision-making on new initiatives continues to be slowed by macroeconomic and geopolitical uncertainty.”
Second-Quarter Results by Segment
Managed services ACV in the second quarter dipped 8 percent, to US $4.0 billion, but rose 3 percent sequentially from a weaker first quarter. A total of 295 managed services contracts were signed in the quarter, up 20 percent from the prior year. Among those contracts were four mega deals (ACV of US $100 million or more), compared with five signed in the second quarter last year. The volume of smaller deals under US $10 million rose 38 percent year on year.
Within managed services, IT outsourcing (ITO) rose 7 percent, to US $3.3 billion, driven by strong growth in bundled infrastructure and application development and maintenance (ADM) services, which offset declines in ADM-only and data center services.
Business process outsourcing (BPO), meanwhile, slumped 45 percent, to US $692 million, as all BPO segments showed declines, especially customer engagement and facilities management services.
By industry, managed services ACV was higher in retail (up 71 percent), manufacturing (up 50 percent) and media and telecom (up 41 percent), while BFSI, Europe’s largest industry for outsourcing, dropped 31 percent year on year, reflecting a higher-for-longer interest rate environment.
ACV in the as-a-service (XaaS) segment climbed 14 percent year on year, to US $3.7 billion, and has grown three straight quarters after hitting bottom in the third quarter of 2023.
Within this segment, infrastructure-as-a-service (IaaS) rose 22 percent, to US $2.7 billion, amid signs the cost-optimization cycle for cloud may be over, due in part to rising interest in data-fueled GenAI. Software-as-a-service (SaaS), meanwhile, was off 2 percent, to US $1.0 billion, as enterprises reduced licensing volume.
Geographic Performance
Although down 13 percent year on year, the region’s largest managed services market, the U.K., posted its sixth straight US $1 billion quarter with ACV in Q2 of US $1.3 billion. The DACH market (Germany, Austria and Switzerland), meanwhile, generated US $896 million of ACV, up 20 percent versus the prior year, its best quarter since the fourth quarter of 2022. Both France (down 12 percent) and the Nordics (down 18 percent) pulled back in the quarter.
First-Half Results
For the first half, combined market ACV rose 3 percent, to US $15.2 billion. Managed services, at US $7.9 billion, was down 3 percent, while XaaS, at US $7.3 billion, was up 11 percent versus the first half last year. A record 571 managed services contracts were signed in the half, up 5 percent, including six mega-deals, even with the prior year.
Within managed services, ITO was essentially flat (down 0.1 percent), at US $6.1 billion, while BPO declined 12 percent, to US $1.8 billion. On the cloud side, the IaaS market rose 15 percent, to US $5.2 billion, while the SaaS market rose 1 percent, to US $2.1 billion.
2024 Global Forecast
For the full year, ISG is forecasting 2 percent revenue growth for managed services, down 100 basis points from its April forecast, and 14 percent revenue growth for XaaS, down from its 15 percent growth forecast in April.
“Uncertainty persists in the IT and business services market, with no clear catalyst at the moment to push discretionary spending higher,” Hall said. “Activity in the important BFSI sector remains dampened, due to the higher-for-longer interest rate environment impacting the overall growth of the market. Enterprises in general continue to focus on cost optimization, and AI growth, while strong, is likely masking underlying weakness in the IT and business services industry.”
About the ISG Index™
The ISG Index™ is recognized as the authoritative source for marketplace intelligence on the global technology and business services industry. For 87 consecutive quarters, it has detailed the latest industry data and trends for financial analysts, enterprise buyers, software and service providers, law firms, universities and the media.
The 2Q24 Global ISG Index results were presented during a webcast today. To view a replay of the webcast and download presentation slides, visit this webpage.
About ISG
ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including AI and automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715801522/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
